VivoSeq
Psychiatry

Attention Deficit Disorder

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Attention Deficit Disorder is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

14/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Unknown status2 · 29%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder
Completed·SShaare Zedek Medical Center·Phase 2·NCT00364702·40 enrolled
Further Studies of Attention Deficit Disorder - Residual Type (RT)
Completed·UUniversity of Utah·Phase 3·NCT00693212·116 enrolled
Attention Deficit Disorder Medication Response Study
Completed·—·Phase 4·NCT01727414·171 enrolled
Treatment of Patients With Alcoholism and Attention Deficit Disorder
Completed·National Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 4·NCT00261872·100 enrolled
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03481959·3 enrolled
The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders
Unknown status·—·N/A·NCT04727476·413 enrolled
The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder
Unknown status·HHaEmek Medical Center, Israel·N/A·NCT02344784·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)